Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study

International Journal of Gynecological Cancer

Volumn 7, Issue 6, 1997, Pages 445-450

  Gadducci, A ^a   Sartori, E ^b   Maggino, T ^c   Zola, P ^d   Landoni, F ^e   Fanucchi, A ^a   Stegher, C ^b   Alessi, C ^c   Buttitta, F ^a   Bergamino, T ^f  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f NONE

Author keywords

Grade; Histologic type; Ovarian cancer; Prognosis; Recurrence; Stage

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 6844237649     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.09742.x     Document Type: Article

References (37)

1. Pettersson F (ed). Annual report on the results of treatment in gynecological cancer (Vol. 21). Int J Gynecol Obstet 1991; 36 (Suppl): 1-315.
2. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993; 71 (Suppl): 1534-1540.
3. Guthrie D. "Early" ovarian cancer: The European experience. In: Conte PF, Ragni N, Rosso R, Vermerken JB, eds. Multimodal Treatment of Ovarian Cancer. New York: Raven Press, 1989, 87-93.
4. Mangioni C, Chiari S, Colombo N, et al. Limited surgery in epithelial ovarian cancer (experience with 93 cases). In: Conte PF, Ragni N, Rosso R, Vermerken JB, eds. Multimodal Treatment of Ovarian Cancer. New York: Raven Press, 1989; 127-132.
5. DiSaia P. Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 1990; 16: 35-42.
6. Rodriguez M, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994; 73: 1245-1250.
7. Trimbos JB, Schueler JA, van der Burg M, et al. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991; 67: 597-602.
8. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072-3076.
9. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-1559.
10. Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: A random trial between postoperative irradiation and chemotherapy. Monogr Natl Cancer Inst 1975; 42: 149-153.
11. Dembo AJ, Bush RS, Beale FA, et al. Ovarian carcinoma: Improved survival following abdomino-pelvic irradiation in patients with complete pelvic operation. Am J Obstet Gynecol 1979; 134: 793-800.
12. Klaassen D, Shelley W, Starreveld A, et al. Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trials Group Report. J Clin Oncol 1988; 6: 1254-1263.
13. Young R, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Result of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.
14. Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cis-platin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741-749.
15. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: Results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 1995; 6: 887-893.
16. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-273.
17. Piver MS, Malfetano J, Baker TR, Hempling RE. Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992; 46: 357-360.
18. Rubin SC, Wong GYC, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Platinum-based chemotherapy in high-risk stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82: 143-147.
19. Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170: 656-662.
20. Malmstrom H, Simonsen E, Westberg R. A Phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 1994; 52: 20-25.
21. Schueler JA, Cornelisse CJ, Hermans J, Trimbos JB, Van der Burg MEL, Fleuren GJ. Prognostic factors in well-differentiated early-stage epithelial ovarian cancer. Cancer 1993; 71: 787-795.
22. Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993; 48: 38-49.
23. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86: 259-264.
24. Smith JP, Day TG. Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 1979; 138: 984-993.
25. Sevelda P, Dittrich C, Salzer H. Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol 1989; 35: 321-322.
26. Finn CB, Luesley DM, Buxton EJ, et al. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 1992; 99: 54-58.
27. Webb MJ, Decker DG, Mussey E, Williams TJ. Factors influencing survival in stage I ovarian cancer. Am J Obstet Gynecol 1973; 116: 222-226.
28. Monga M, Carmichael JA, Shelley WE, et al. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991; 43: 195-197.
29. Sainz de la Cuesta R, Goff BA, Fuller AF, Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84: 1-7.
30. Nasu K, Hirota Y, Kawano Y, Matsui N, Hayata T, Miyakawa I. Characterization of intraoperative rotture of epithelial ovarian cancer at early stage. Nippon Sanka Fujinka Gakkai Zasshi 1995; 47: 907-910.
31. Creasman WT, Omura GA, Brady MF, Yordan E, DiSaia PJ, Beecham J. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without Bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1990; 39: 239-243.
32. Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO sub-stage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995; 56: 175-180.
33. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): Bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-254.
34. Lentz SS, Cha SS, Wieand HS, Podratz CK. Stage I ovarian epithelial carcinoma: Survival analysis following definitive treatment. Gynecol Oncol 1991; 43: 198-202.
35. Walton L, Ellemberg SS, Major FJ, Miller A, Park R, Young RC. Results of second-look laparotomy in patients with early-stage ovarian carcinoma. Obstet Gynecol 1987; 70: 770-773.
36. Rubin SC, Jones WB, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82: 139-142.
37. NIH Consensus Conference. Ovarian Cancer screening, treatment, and follow-up. JAMA 1995; 273: 491-497.